Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AJN004
- Development stage
- Preclinical
- Lead developer
- AltrixBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AJN004 is an orally administered small molecule therapeutic candidate being developed by AltrixBio for the treatment of post-bariatric hypoglycemia (PBH), also known as reactive hypoglycemia. PBH is a complication of gastric bypass surgery characterized by the excessive secretion of incretin hormones (such as GLP-1) in response to nutrient ingestion, which triggers an exaggerated insulin response and subsequent dangerous drops in blood glucose levels. AJN004 is designed to blunt this incretin over-secretion, thereby stabilizing glucose metabolism and preventing hypoglycemic episodes. The drug is currently in the preclinical stage of development.
Beyond the preview
Go deeper on AJN004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AJN004.